Qi Ben-ling, Cheng Bei, Zhang Qiao-hong
Department of Geriatrics, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004 May;24(5):404-7.
To explore the anti-atherosclerosis effect of Taizhi'an Capsule (TZA) for providing a theoretical base of its application in preventing coronary heart disease (CHD), by way of observing the effects of TZA and pravastatin (PVT) on vascular endothelial function in senile patients with CHD.
Seventy-eight Senile patients with CHD were randomly divided into the TZA group and the PVT group, 39 in each group. Changes of carotid arterial intima-media thickness (IMT) and brachial arterial endothelium dependent diastolic function (FMD) before and after treatment were observed by non-invasive ultrasound test technique, and levels of serum nitric oxide (NO) and plasma endothelin-1 (ET-1) were determined as well.
After TAZ treatment, IMT decreased from 1.21 +/- 0.17 mm to 0.91 +/- 0.13 mm, FMD increased from 5.02 +/- 0.58% to 8.97 +/- 0.39%, ET-1 lowered from 95.93 +/- 19.41 ng/L to 49.35 +/- 53.27 ng/L, and NO enhanced from 42.56 +/- 14.12 mumol/L to 69.84 +/- 21.96 mumol/L; after PVT treatment, the corresponding changes were 1.25 +/- 0.21 mm to 0.88 +/- 0.32 mm, 4.90 +/- 0.37% to 8.12 +/- 0.25%, 89.35 +/- 10.02 ng/L to 47.96 +/- 11.05 ng/L and 51.71 +/- 9.39 mumol/L to 72.93 +/- 16.51 mumol/L, all the changes were statistically significant.
TZA can obviously improve the vascular endothelial function in old patients with CHD, which has the anti-atherosclerosis effect similar to that of PVT.
通过观察泰脂安胶囊(TZA)和普伐他汀(PVT)对老年冠心病(CHD)患者血管内皮功能的影响,探讨泰脂安胶囊的抗动脉粥样硬化作用,为其在冠心病防治中的应用提供理论依据。
将78例老年冠心病患者随机分为TZA组和PVT组,每组39例。采用无创超声检测技术观察治疗前后颈动脉内膜中层厚度(IMT)和肱动脉内皮依赖性舒张功能(FMD)的变化,并检测血清一氧化氮(NO)和血浆内皮素-1(ET-1)水平。
TAZ治疗后,IMT从1.21±0.17mm降至0.91±0.13mm,FMD从5.02±0.58%升至8.97±0.39%,ET-1从95.93±19.41ng/L降至49.35±53.27ng/L,NO从42.56±14.12μmol/L升至69.84±21.96μmol/L;PVT治疗后,相应变化为1.25±0.21mm降至0.88±0.32mm,4.90±0.37%升至8.12±0.25%,89.35±10.02ng/L降至47.96±11.05ng/L,51.71±9.39μmol/L升至72.93±16.51μmol/L,所有变化均有统计学意义。
TZA能明显改善老年冠心病患者的血管内皮功能,其抗动脉粥样硬化作用与PVT相似。